Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc [More Details]
Low-Dose Naltrexone in Rheumatological Diseases
Mediterr J Rheumatol
31 March 2023
https://pubmed.ncbi.nlm.nih.gov/37223594/
Background: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders.
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
Biomedicines
As revised 23 March 2023
https://www.mdpi.com/2227-9059/11/4/1087
Marilyn - US: RA Pain (LDN; low dose naltrexone)
Linda: Welcome to the LDN radio show brought to you by the LDN Research Trust. I'm your host Linda Elsegood. I have an exciting lineup of guest speakers who are LDN experts in their field. We will be discussing low dose naltrexone and its many uses in autoimmune diseases, cancers, etc. Thank you for joining us.
The LDN 3: To Purchase with discounts before 1st September 2022 Go to ldnresearchtrust.org/ldn-book-3 for full details
LDN Webinar Presentation 18 May 2022: Dr Mathewson - LDN as supportive care for Oncology and Autoimmune patients: Case Reviews
Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/
Pagination
- Page 1
- Next page